The Patent Finder
US

Biphenyl Compounds Useful as Muscarinic Receptor Antagonists

US 12,258,316 Term ended
OverviewFamilyAssignmentsSources & methods

Also listed on Theravance, Inc., an earlier holder on the record. The recorded assignments below show how it moved.

Term ended Oct 23, 2026 · Medium confidence

Why Medium: A parent in the chain could not be resolved.

Filed Jan 5, 2022 as application 17/569,255 · Granted Mar 25, 2025
Base term plus 592 days of patent term adjustment (USPTO delay)
Today
20 years from filing
Term ended Oct 23, 2026
2005 2026
Clock starts
Mar 10, 2005
Term ended
Oct 23, 2026
Granted
Mar 25, 2025
base term patent term adjustment after the term ends Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
592
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
None due
Maintenance fees
This term ends before the first maintenance fee's grace period does, 4 years from grant, so no fee can end it early.
16
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.

This patent's term runs 592 days past its 20-year base term on prosecution delay. Confidence: Medium. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts Mar 10, 2005, when application 11/077,433, the earliest non-provisional in its chain, was filed (this one was filed Jan 5, 2022); a parent in its chain could not be resolved (the next row)Mar 10, 2025High confidence
Continuity chainA parent in the chain could not be resolveddated from this application's own claimMedium confidence
Patent term adjustment+592 days, USPTO patent term adjustment recordOct 23, 2026High confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee eventsNo maintenance fee can end the term earlyterm endedHigh confidence
Computed term endThe steps above, in orderOct 23, 2026Medium confidence

This family

US 7,288,657In force
Oct 2028
Oct 2028
US 8,017,783In force
Jan 2028
Jan 2028
US 8,912,334Term ended
Mar 2025
Mar 2025
US 12,258,316this patent
Oct 2026
Oct 2026
4 of 16 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Sep 24, 2026
Reel 76134, frame 790
Theravance Biopharma R&D IP, LLCU.S. Bank Trust Company, National AssociationSecurity Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited